The National Health Service in England could double the annual payments it offers companies under its pioneering subscription-style contracts for incentivizing them to develop new antibiotics from £10m ($12.90m) to £20m, where outstanding clinically based criteria are met.
In proposals announced today for a 12-week public consultation, NHS England is also seeking input on which products to prioritize,...